LBCL
The largest study yet comparing chimeric antigen receptor (CAR) T-cell therapy with the previous standard of care (SOC)...
In second-line therapy for relapsed/refractory LBCL, which patients would you consider eligible for CAR T-cell therapy...
Axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell treatment, improved quality of life compared to standard of care ...
Advertisement
Axicabtagene ciloleucel is the most cost-effective chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed ...
Results from the global, phase III TRANSFORM study support liso-cel as a new second-line treatment recommendation in patients ...
The overall efficacy of tisagenlecleucel was similar between the two groups. Flu/Cy led to more profound lymphocytopenia ...
Advertisement
In the study, 11 patients with relapsed/refractory diffuse LBCL were infused with anbal-cel.
Epcoritamab is a subcutaneous CD3/CD20 bispecific antibody that induces anti-tumor activity across B-cell NHL subtypes.
The FDA previously approved this treatment for adults with R/R LBCL or FL who received two or more lines of systemic therapy.
The primary analysis of the study was published in Nature Medicine by Sattva S. Neelapu, MD.
According to data from the ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) ...
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.